This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biotech Stock Mailbag: Avanir Pharma

FDA, of course, will be the ultimate arbiter, and I won't be surprised to see the agency convene an advisory panel to review AZ-004 in the fall or toward the end of the year.

Without details from the Alexza resubmission or insight into FDA's thinking, passing judgment on the staccato device is difficult. Be aware that FDA, historically, has set a high safety bar for companies seeking to develop inhaled drugs, although such drugs have been approved. i.e., Nektar's Therapeutics (NKTR) inhaled insulin.

I have doubts about the clinical utility of an inhaled drug for schizophrenia because I don't see the advantages over injections, especially in the hospital setting. However, an approval of AZ-004 will validate Alexza's drug-delivery technology and boost the value of its other pipeline products, some of which like migraine, panic attacks and insomnia, have certain advantages over current therapies.

Alexza ended last year with $42 million but the company needs to raise additional cash before the end of the third quarter. New money could come from the signing of a new development partner, but I have a difficult time believing any partner will sign on until FDA weighs in the lung safety of staccato.

Alexza shares fell below $1 following the FDA's rejection of AZ-004 last fall but the stock has rebounded, especially in the past couple of weeks after management reiterated plans to resubmit AZ-004 to FDA in July. Alexza closed Thursday at $1.70.

Hank O. emails, " Pharmasset (VRUS) is on a remarkable run. Is this sustainable or justified? The hepatitis C drugs are so early in clinical trials."

Remarkable is an apt description for the roughly 50% move in Pharmasset's stock during March. And even with the stock at $78 now, Pharmasset's enterprise value is still only around $2.5 billion compared to Vertex Pharmaceuticals' (VRTX) $9 billion enterprise value.

Is Pharmasset way undervalued? Is Vertex a bloated pig? A bit of both, perhaps?

Vertex is well ahead of Pharmasset in the race to approval of their respective Hep C drugs, but the buzz is definitely in Pharmasset's camp, especially in regard to the drugs PSI-938 and PSI-7977, which the company owns full rights to. Data being presented on both drugs at the European Association for the Study of Liver Disease (EASL) meeting right now bolster the promising data previewed in research abstracts released in early March.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ALXA $2.18 3.30%
AVNR $16.96 0.00%
RXII $1.14 -1.70%
AAPL $129.40 0.73%
FB $79.61 0.81%


DOW 18,253.33 +120.63 0.67%
S&P 500 2,113.23 +8.73 0.41%
NASDAQ 4,997.1710 +33.6440 0.68%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs